Literature DB >> 3818255

Ketanserin, a 5-HT antagonist, in symptomatic treatment of carcinoid syndrome.

P A Sullivan, M O'Donovan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3818255     DOI： 10.1007/bf02940548

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN： 0021-1265            Impact factor:   1.568


× No keyword cloud information.
  4 in total

1.  Argentaffinoma as endocrine tumour.

Authors:  I H PAGE; A C CORCORAN; S UDENFRIEND; A SZOEDSMA; H WEISSBACH
Journal:  Lancet       Date:  1955-01-22       Impact factor: 79.321

2.  Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors.

Authors:  J E Leysen; F Awouters; L Kennis; P M Laduron; J Vandenberk; P A Janssen
Journal:  Life Sci       Date:  1981-03-02       Impact factor: 5.037

3.  Evidence for 5-HT2 receptors mediating contraction in vascular smooth muscle.

Authors:  M L Cohen; R W Fuller; K S Wiley
Journal:  J Pharmacol Exp Ther       Date:  1981-08       Impact factor: 4.030

4.  Serotonin (5-hydroxytryptamine); the last four years.

Authors:  I H PAGE
Journal:  Physiol Rev       Date:  1958-04       Impact factor: 37.312
  4 in total
  1 in total

Review 1.  Carcinoid syndrome and serotonin: therapeutic effects of ketanserin.

Authors:  J I Robertson
Journal:  Cardiovasc Drugs Ther       Date:  1990-01       Impact factor: 3.727
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.